Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
About this study
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Condition
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Tested
- 86-Gallium PSMA PET/CT
- Sponsor
- The Netherlands Cancer Institute
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 12
- Study condition: Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- For all groups:
- Written informed consent
- Age ≥ 18 years old
- WHO PS 0-3
- Measurable lesion ≥10mm according to RANO BM
- For brain metastases groups:
- \- newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7).
- For radiation necrosis groups:
- \- Brain lesion at the location of a formerly brain metastases that has been treated with SRT (\> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and/ or breast cancer (group 8).
- For diagnostic dilemma groups:
- \- Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and/ or breast cancer (group 9).
Exclusion 6
- For all groups:
- Known allergy to Ga68-PSMA
- Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan
- Life expectancy less than 3 months
- Patients with known prostate carcinoma
- Pregnancy
Where
1 site, 1 recruiting
Netherlands Cancer Institute - Antoni van Leeuwenhoek
Amsterdam, Netherlands
Contact
-
Lente Kroon, MD
0031205129111 neurologie@nki.nl
-
Dieta Brandsma, MD, PhD
Potential match only. Final eligibility is determined by the study team.